Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic
Authors:
- 14 May 2013
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1291 (1) , 33-41
Abstract
Clostridium difficile infection, also known as C. difficile-associated diarrhea (CDAD), is the most common cause of nosocomial diarrhea, typically initiated by the use of broad-spectrum antibiotics that disrupt gut flora, thereby allowing C. difficile to proliferate. It is an increasing cause of morbidity and mortality, especially in hospitals and long-term care facilities. A particularly challenging aspect to treating CDAD has been maintenance of clinical response: following initial treatment success, recurrence occurs in approximately 15-30% of patients after the first episode and up to 50-60% subsequently. Fidaxomicin, marketed as DIFICID® in the United States, is approved in multiple countries and is the first new drug to be approved for this indication in over 25 years. It is a novel, narrow spectrum antibiotic with potent bactericidal activity against C. difficile and low activity against the normal gut microbiota. In clinical trials, fidaxomicin has been shown to be noninferior in initial clinical response to CDAD compared to vancomycin, and superior in limiting recurrence and providing sustained clinical response. In this review, the development and characteristics of fidaxomicin are described.Keywords
This publication has 39 references indexed in Scilit:
- Fidaxomicin Inhibits Spore Production in Clostridium difficileClinical Infectious Diseases, 2012
- Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA SynthesisClinical Infectious Diseases, 2012
- Antimicrobial Activities of FidaxomicinClinical Infectious Diseases, 2012
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus VancomycinClinical Infectious Diseases, 2012
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDIClinical Infectious Diseases, 2012
- The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based StudyAmerican Journal of Gastroenterology, 2012
- Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficileAntimicrobial Agents and Chemotherapy, 2011
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent InfectionsClinical Infectious Diseases, 2011
- Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients withClostridium difficileInfectionAntimicrobial Agents and Chemotherapy, 2009
- Ontario's hospitals surpass those of Quebec in C. difficile ratesCanadian Medical Association Journal, 2008